25 XP   0   0   10

Telix Pharmaceuticals Ltd
Buy, Hold or Sell?

Let's analyse Telix Pharmaceuticals Ltd together

PenkeI guess you are interested in Telix Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Telix Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Telix Pharmaceuticals Ltd

I send you an email if I find something interesting about Telix Pharmaceuticals Ltd.

Quick analysis of Telix Pharmaceuticals Ltd (30 sec.)










What can you expect buying and holding a share of Telix Pharmaceuticals Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
28.6%

What is your share worth?

Current worth
A$0.46
Expected worth in 1 year
A$1.28
How sure are you?
85.7%

+ What do you gain per year?

Total Gains per Share
A$0.82
Return On Investment
5.8%

For what price can you sell your share?

Current Price per Share
A$14.30
Expected price per share
A$11.16 - A$
How sure are you?
50%

1. Valuation of Telix Pharmaceuticals Ltd (5 min.)




Live pricePrice per Share (EOD)

A$14.30

Intrinsic Value Per Share

A$-0.51 - A$0.16

Total Value Per Share

A$-0.05 - A$0.62

2. Growth of Telix Pharmaceuticals Ltd (5 min.)




Is Telix Pharmaceuticals Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$96m$53m$43m44.8%

How much money is Telix Pharmaceuticals Ltd making?

Current yearPrevious yearGrowGrow %
Making money$3.3m-$67.1m$70.5m2,097.3%
Net Profit Margin1.0%-65.0%--

How much money comes from the company's main activities?

3. Financial Health of Telix Pharmaceuticals Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#377 / 1009

Most Revenue
#46 / 1009

Most Profit
#118 / 1009

Most Efficient
#153 / 1009

What can you expect buying and holding a share of Telix Pharmaceuticals Ltd? (5 min.)

Welcome investor! Telix Pharmaceuticals Ltd's management wants to use your money to grow the business. In return you get a share of Telix Pharmaceuticals Ltd.

What can you expect buying and holding a share of Telix Pharmaceuticals Ltd?

First you should know what it really means to hold a share of Telix Pharmaceuticals Ltd. And how you can make/lose money.

Speculation

The Price per Share of Telix Pharmaceuticals Ltd is A$14.30. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Telix Pharmaceuticals Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Telix Pharmaceuticals Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.46. Based on the TTM, the Book Value Change Per Share is A$0.21 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Telix Pharmaceuticals Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.010.1%0.010.1%-0.21-1.4%-0.10-0.7%-0.08-0.5%
Usd Book Value Change Per Share0.130.9%0.130.9%0.161.1%0.040.3%0.040.3%
Usd Dividend Per Share0.000.0%0.000.0%0.342.3%0.080.6%0.060.4%
Usd Total Gains Per Share0.130.9%0.130.9%0.493.4%0.120.8%0.100.7%
Usd Price Per Share6.50-6.50-4.69-3.93-2.92-
Price to Earnings Ratio626.72-626.72--22.63-105.52-68.70-
Price-to-Total Gains Ratio48.92-48.92-9.54-16.48-20.68-
Price to Book Ratio21.93-21.93-28.67-152.50-110.08-
Price-to-Total Gains Ratio48.92-48.92-9.54-16.48-20.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.22636
Number of shares108
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.08
Usd Book Value Change Per Share0.130.04
Usd Total Gains Per Share0.130.12
Gains per Quarter (108 shares)14.3612.86
Gains per Year (108 shares)57.4351.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105747351741
20115104703392
3017216110550143
4023021814066194
5028727517583245
6034533220999296
70402389244116347
80459446279132398
90517503314149449
100574560349165500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%1.06.00.014.3%1.06.00.014.3%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%6.01.00.085.7%6.01.00.085.7%
Dividend per Share0.00.01.00.0%1.00.02.033.3%2.00.03.040.0%2.00.05.028.6%2.00.05.028.6%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%6.01.00.085.7%6.01.00.085.7%

Fundamentals of Telix Pharmaceuticals Ltd

About Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-04-09 05:38:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Telix Pharmaceuticals Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Telix Pharmaceuticals Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Telix Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 1.0% means that $0.01 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 1.0%. The company is making a profit. +1
  • The TTM is 1.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.0%0.0%
TTM1.0%YOY-65.0%+66.1%
TTM1.0%5Y-556.9%+558.0%
5Y-556.9%10Y-1,636.0%+1,079.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-200.1%+201.1%
TTM1.0%-216.8%+217.8%
YOY-65.0%-288.3%+223.3%
5Y-556.9%-449.1%-107.8%
10Y-1,636.0%-605.5%-1,030.5%
1.1.2. Return on Assets

Shows how efficient Telix Pharmaceuticals Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Telix Pharmaceuticals Ltd to the Biotechnology industry mean.
  • 1.3% Return on Assets means that Telix Pharmaceuticals Ltd generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 1.3%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.3%TTM1.3%0.0%
TTM1.3%YOY-39.9%+41.2%
TTM1.3%5Y-33.3%+34.6%
5Y-33.3%10Y-28.1%-5.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3%-13.3%+14.6%
TTM1.3%-12.8%+14.1%
YOY-39.9%-11.7%-28.2%
5Y-33.3%-13.9%-19.4%
10Y-28.1%-15.7%-12.4%
1.1.3. Return on Equity

Shows how efficient Telix Pharmaceuticals Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Telix Pharmaceuticals Ltd to the Biotechnology industry mean.
  • 3.5% Return on Equity means Telix Pharmaceuticals Ltd generated $0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 3.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.5%TTM3.5%0.0%
TTM3.5%YOY-130.1%+133.6%
TTM3.5%5Y-790.8%+794.3%
5Y-790.8%10Y-570.4%-220.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5%-16.9%+20.4%
TTM3.5%-16.1%+19.6%
YOY-130.1%-15.1%-115.0%
5Y-790.8%-19.3%-771.5%
10Y-570.4%-20.2%-550.2%

1.2. Operating Efficiency of Telix Pharmaceuticals Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Telix Pharmaceuticals Ltd is operating .

  • Measures how much profit Telix Pharmaceuticals Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Telix Pharmaceuticals Ltd to the Biotechnology industry mean.
  • An Operating Margin of 3.4% means the company generated $0.03  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 3.4%. The company is operating less efficient.
  • The TTM is 3.4%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ3.4%TTM3.4%0.0%
TTM3.4%YOY-45.7%+49.1%
TTM3.4%5Y-576.1%+579.6%
5Y-576.1%10Y-1,785.2%+1,209.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4%-296.2%+299.6%
TTM3.4%-232.5%+235.9%
YOY-45.7%-298.2%+252.5%
5Y-576.1%-492.1%-84.0%
10Y-1,785.2%-632.4%-1,152.8%
1.2.2. Operating Ratio

Measures how efficient Telix Pharmaceuticals Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.92 means that the operating costs are $0.92 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 0.921. The company is less efficient in keeping operating costs low.
  • The TTM is 0.921. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.921TTM0.9210.000
TTM0.921YOY1.457-0.536
TTM0.9215Y7.415-6.494
5Y7.41510Y27.993-20.579
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9213.231-2.310
TTM0.9213.310-2.389
YOY1.4573.890-2.433
5Y7.4155.739+1.676
10Y27.9937.876+20.117

1.3. Liquidity of Telix Pharmaceuticals Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Telix Pharmaceuticals Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.43 means the company has $1.43 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 1.428. The company is just able to pay all its short-term debts.
  • The TTM is 1.428. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.428TTM1.4280.000
TTM1.428YOY2.025-0.596
TTM1.4285Y2.984-1.555
5Y2.98410Y7.573-4.589
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4283.890-2.462
TTM1.4284.173-2.745
YOY2.0255.344-3.319
5Y2.9846.126-3.142
10Y7.5736.448+1.125
1.3.2. Quick Ratio

Measures if Telix Pharmaceuticals Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Telix Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 1.19 means the company can pay off $1.19 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 1.194. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.194. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.194TTM1.1940.000
TTM1.194YOY1.896-0.702
TTM1.1945Y2.834-1.640
5Y2.83410Y7.408-4.574
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1943.514-2.320
TTM1.1943.998-2.804
YOY1.8965.380-3.484
5Y2.8346.105-3.271
10Y7.4086.404+1.004

1.4. Solvency of Telix Pharmaceuticals Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Telix Pharmaceuticals Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Telix Pharmaceuticals Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.63 means that Telix Pharmaceuticals Ltd assets are financed with 62.6% credit (debt) and the remaining percentage (100% - 62.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 0.626. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.626. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.626TTM0.6260.000
TTM0.626YOY0.685-0.059
TTM0.6265Y0.622+0.004
5Y0.62210Y0.493+0.128
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6260.339+0.287
TTM0.6260.336+0.290
YOY0.6850.271+0.414
5Y0.6220.366+0.256
10Y0.4930.389+0.104
1.4.2. Debt to Equity Ratio

Measures if Telix Pharmaceuticals Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Telix Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 167.5% means that company has $1.67 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Telix Pharmaceuticals Ltd:

  • The MRQ is 1.675. The company is just able to pay all its debts with equity.
  • The TTM is 1.675. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.675TTM1.6750.000
TTM1.675YOY2.230-0.555
TTM1.6755Y10.927-9.253
5Y10.92710Y7.875+3.053
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6750.388+1.287
TTM1.6750.402+1.273
YOY2.2300.335+1.895
5Y10.9270.426+10.501
10Y7.8750.461+7.414

2. Market Valuation of Telix Pharmaceuticals Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Telix Pharmaceuticals Ltd generates.

  • Above 15 is considered overpriced but always compare Telix Pharmaceuticals Ltd to the Biotechnology industry mean.
  • A PE ratio of 626.72 means the investor is paying $626.72 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Telix Pharmaceuticals Ltd:

  • The EOD is 889.092. Based on the earnings, the company is expensive. -2
  • The MRQ is 626.716. Based on the earnings, the company is expensive. -2
  • The TTM is 626.716. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD889.092MRQ626.716+262.375
MRQ626.716TTM626.7160.000
TTM626.716YOY-22.631+649.347
TTM626.7165Y105.519+521.198
5Y105.51910Y68.695+36.823
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD889.092-2.264+891.356
MRQ626.716-2.629+629.345
TTM626.716-2.680+629.396
YOY-22.631-4.145-18.486
5Y105.519-6.257+111.776
10Y68.695-6.254+74.949
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Telix Pharmaceuticals Ltd:

  • The EOD is 353.939. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 249.490. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 249.490. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD353.939MRQ249.490+104.449
MRQ249.490TTM249.4900.000
TTM249.490YOY-30.263+279.753
TTM249.4905Y180.882+68.608
5Y180.88210Y122.998+57.884
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD353.939-2.973+356.912
MRQ249.490-3.333+252.823
TTM249.490-3.553+253.043
YOY-30.263-5.605-24.658
5Y180.882-8.376+189.258
10Y122.998-8.865+131.863
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Telix Pharmaceuticals Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 21.93 means the investor is paying $21.93 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Telix Pharmaceuticals Ltd:

  • The EOD is 31.113. Based on the equity, the company is expensive. -2
  • The MRQ is 21.931. Based on the equity, the company is expensive. -2
  • The TTM is 21.931. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD31.113MRQ21.931+9.182
MRQ21.931TTM21.9310.000
TTM21.931YOY28.670-6.739
TTM21.9315Y152.502-130.571
5Y152.50210Y110.081+42.421
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD31.1131.896+29.217
MRQ21.9312.115+19.816
TTM21.9312.093+19.838
YOY28.6702.884+25.786
5Y152.5023.542+148.960
10Y110.0813.916+106.165
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Telix Pharmaceuticals Ltd.

3.1. Funds holding Telix Pharmaceuticals Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-02-28SPDR Portfolio Developed World ex-US ETF0.04-101786--
2021-02-28SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF0.029999999-97238--
Total 0.069999999019902400.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Telix Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.2060.2060%0.242-15%0.059+248%0.066+214%
Book Value Per Share--0.4600.4600%0.254+81%0.238+93%0.215+114%
Current Ratio--1.4281.4280%2.025-29%2.984-52%7.573-81%
Debt To Asset Ratio--0.6260.6260%0.685-9%0.622+1%0.493+27%
Debt To Equity Ratio--1.6751.6750%2.230-25%10.927-85%7.875-79%
Dividend Per Share----0%0.520-100%0.125-100%0.089-100%
Eps--0.0160.0160%-0.321+2097%-0.156+1068%-0.120+847%
Free Cash Flow Per Share--0.0400.0400%-0.240+695%-0.091+325%-0.077+290%
Free Cash Flow To Equity Per Share--0.0720.0720%0.300-76%0.072-1%0.064+13%
Gross Profit Margin---9.529-9.5290%1.156-925%-1.052-89%-0.455-95%
Intrinsic Value_10Y_max--0.160--------
Intrinsic Value_10Y_min---0.514--------
Intrinsic Value_1Y_max---0.068--------
Intrinsic Value_1Y_min---0.111--------
Intrinsic Value_3Y_max---0.141--------
Intrinsic Value_3Y_min---0.283--------
Intrinsic Value_5Y_max---0.136--------
Intrinsic Value_5Y_min---0.400--------
Market Cap4633057228.800+30%3265819361.2803265819361.2800%2355407416.320+39%1971803237.376+66%1467211929.600+123%
Net Profit Margin--0.0100.0100%-0.650+6296%-5.569+53179%-16.360+156029%
Operating Margin--0.0340.0340%-0.457+1433%-5.761+16905%-17.852+52173%
Operating Ratio--0.9210.9210%1.457-37%7.415-88%27.993-97%
Pb Ratio31.113+30%21.93121.9310%28.670-24%152.502-86%110.081-80%
Pe Ratio889.092+30%626.716626.7160%-22.631+104%105.519+494%68.695+812%
Price Per Share14.300+30%10.08010.0800%7.270+39%6.086+66%4.529+123%
Price To Free Cash Flow Ratio353.939+30%249.490249.4900%-30.263+112%180.882+38%122.998+103%
Price To Total Gains Ratio69.404+30%48.92248.9220%9.539+413%16.479+197%20.683+137%
Quick Ratio--1.1941.1940%1.896-37%2.834-58%7.408-84%
Return On Assets--0.0130.0130%-0.399+3153%-0.333+2644%-0.281+2250%
Return On Equity--0.0350.0350%-1.301+3817%-7.908+22698%-5.704+16401%
Total Gains Per Share--0.2060.2060%0.762-73%0.185+12%0.155+33%
Usd Book Value--96077377.20096077377.2000%53007051.200+81%49653043.520+93%44886122.038+114%
Usd Book Value Change Per Share--0.1330.1330%0.156-15%0.038+248%0.042+214%
Usd Book Value Per Share--0.2970.2970%0.164+81%0.153+93%0.139+114%
Usd Dividend Per Share----0%0.335-100%0.081-100%0.058-100%
Usd Eps--0.0100.0100%-0.207+2097%-0.100+1068%-0.077+847%
Usd Free Cash Flow--8445668.0008445668.0000%-50216561.200+695%-19042561.840+325%-16070761.146+290%
Usd Free Cash Flow Per Share--0.0260.0260%-0.155+695%-0.059+325%-0.050+290%
Usd Free Cash Flow To Equity Per Share--0.0460.0460%0.193-76%0.047-1%0.041+13%
Usd Market Cap2989248524.022+30%2107106651.8982107106651.8980%1519708865.010+39%1272207448.755+66%946645136.978+123%
Usd Price Per Share9.226+30%6.5046.5040%4.691+39%3.927+66%2.922+123%
Usd Profit--3362137.2003362137.2000%-67151770.800+2097%-32535113.280+1068%-25101869.155+847%
Usd Revenue--320444386.800320444386.8000%103293939.200+210%86850242.960+269%62091062.475+416%
Usd Total Gains Per Share--0.1330.1330%0.492-73%0.119+12%0.100+33%
 EOD+4 -4MRQTTM+0 -0YOY+22 -145Y+25 -1110Y+27 -9

4.2. Fundamental Score

Let's check the fundamental score of Telix Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15889.092
Price to Book Ratio (EOD)Between0-131.113
Net Profit Margin (MRQ)Greater than00.010
Operating Margin (MRQ)Greater than00.034
Quick Ratio (MRQ)Greater than11.194
Current Ratio (MRQ)Greater than11.428
Debt to Asset Ratio (MRQ)Less than10.626
Debt to Equity Ratio (MRQ)Less than11.675
Return on Equity (MRQ)Greater than0.150.035
Return on Assets (MRQ)Greater than0.050.013
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Telix Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.107
Ma 20Greater thanMa 5012.862
Ma 50Greater thanMa 10012.143
Ma 100Greater thanMa 20011.274
OpenGreater thanClose14.280
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Income before Tax  -31,122-29,131-60,253-38,786-99,039417-98,622101,7093,087
Net Income  -27,867-17,020-44,887-35,623-80,510-23,569-104,079109,2905,211
EBIT  -28,714-20,539-49,253-31,994-81,2478,067-73,18090,20717,027
EBITDA  -24,478-19,893-44,371-31,702-76,0738,272-67,80191,57123,770
Operating Income  -28,714-20,539-49,253-31,994-81,2478,067-73,18090,20717,027
Net Income from Continuing Operations  -27,867-17,020-44,887-35,623-80,510-23,569-104,079109,2905,211



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets398,302
Total Liabilities249,391
Total Stockholder Equity148,911
 As reported
Total Liabilities 249,391
Total Stockholder Equity+ 148,911
Total Assets = 398,302

Assets

Total Assets398,302
Total Current Assets224,848
Long-term Assets173,454
Total Current Assets
Cash And Cash Equivalents 123,237
Net Receivables 64,777
Inventory 17,310
Other Current Assets 7,102
Total Current Assets  (as reported)224,848
Total Current Assets  (calculated)212,426
+/- 12,422
Long-term Assets
Property Plant Equipment 30,493
Goodwill 4,847
Long Term Investments 12,260
Intangible Assets 104,816
Long-term Assets Other 586
Long-term Assets  (as reported)173,454
Long-term Assets  (calculated)153,002
+/- 20,452

Liabilities & Shareholders' Equity

Total Current Liabilities157,408
Long-term Liabilities91,983
Total Stockholder Equity148,911
Total Current Liabilities
Short-term Debt 1,559
Short Long Term Debt 964
Accounts payable 32,837
Other Current Liabilities 10,995
Total Current Liabilities  (as reported)157,408
Total Current Liabilities  (calculated)46,355
+/- 111,053
Long-term Liabilities
Long term Debt 8,209
Capital Lease Obligations 8,272
Long-term Liabilities Other 12,162
Long-term Liabilities  (as reported)91,983
Long-term Liabilities  (calculated)28,643
+/- 63,340
Total Stockholder Equity
Common Stock446,268
Retained Earnings -263,665
Accumulated Other Comprehensive Income -33,692
Total Stockholder Equity (as reported)148,911
Total Stockholder Equity (calculated)148,911
+/-0
Other
Capital Stock446,268
Cash and Short Term Investments 123,237
Common Stock Shares Outstanding 323,710
Current Deferred Revenue112,017
Liabilities and Stockholders Equity 398,302
Net Debt -105,792
Net Invested Capital 158,084
Net Working Capital 67,440
Property Plant and Equipment Gross 36,309
Short Long Term Debt Total 17,445



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312000-12-311999-12-31
> Total Assets 
0
9,394
51,094
76,708
102,608
164,442
109,813
260,591
398,302
398,302260,591109,813164,442102,60876,70851,0949,3940
   > Total Current Assets 
0
3,049
49,545
35,856
58,679
93,628
47,543
173,233
224,848
224,848173,23347,54393,62858,67935,85649,5453,0490
       Cash And Cash Equivalents 
0
2,994
48,759
25,771
44,598
77,945
22,037
116,329
123,237
123,237116,32922,03777,94544,59825,77148,7592,9940
       Net Receivables 
0
55
489
8,436
12,071
14,191
20,845
45,919
64,777
64,77745,91920,84514,19112,0718,436489550
       Other Current Assets 
0
0
297
1,007
938
859
1,207
2,508
7,102
7,1022,5081,2078599381,00729700
   > Long-term Assets 
0
6,345
1,549
40,852
43,929
70,814
62,270
87,358
173,454
173,45487,35862,27070,81443,92940,8521,5496,3450
       Property Plant Equipment 
0
6,345
5
226
1,899
4,821
6,329
18,838
30,493
30,49318,8386,3294,8211,89922656,3450
       Goodwill 
0
0
332
3,140
4,224
4,224
4,097
5,519
4,847
4,8475,5194,0974,2244,2243,14033200
       Long Term Investments 
0
0
0
0
0
0
0
0
12,260
12,26000000000
       Intangible Assets 
0
0
1,176
36,311
37,724
59,189
55,729
58,984
104,816
104,81658,98455,72959,18937,72436,3111,17600
       Other Assets 
0
0
35
1,175
82
183
212
3,971
0
03,971212183821,1753500
> Total Liabilities 
0
352
1,801
23,804
32,527
84,444
106,171
178,435
249,391
249,391178,435106,17184,44432,52723,8041,8013520
   > Total Current Liabilities 
0
352
1,468
8,242
10,625
19,956
37,982
85,556
157,408
157,40885,55637,98219,95610,6258,2421,4683520
       Short-term Debt 
0
0
345
1,133
490
767
632
641
1,559
1,5596416327674901,13334500
       Short Long Term Debt 
0
0
345
1,133
469
264
19
0
964
9640192644691,13334500
       Accounts payable 
0
0
276
3,249
6,964
5,808
11,884
16,806
32,837
32,83716,80611,8845,8086,9643,24927600
       Other Current Liabilities 
0
0
847
3,860
3,171
10,146
19,323
63,169
10,995
10,99563,16919,32310,1463,1713,86084700
   > Long-term Liabilities 
0
0
332
15,562
21,902
64,488
68,189
92,879
91,983
91,98392,87968,18964,48821,90215,56233200
       Long term Debt Total 
0
0
0
596
1,641
1,440
1,907
9,805
0
09,8051,9071,4401,641596000
       Other Liabilities 
0
0
332
14,966
20,261
57,409
67,766
79,985
0
079,98567,76657,40920,26114,96633200
> Total Stockholder Equity
0
9,042
49,293
52,904
70,081
79,016
2,158
80,007
148,911
148,91180,0072,15879,01670,08152,90449,2939,0420
   Common Stock
0
15,121
55,561
72,053
115,943
167,058
170,840
370,972
446,268
446,268370,972170,840167,058115,94372,05355,56115,1210
   Retained Earnings Total Equity000000000
   Accumulated Other Comprehensive Income 
0
0
109
1,059
2,212
4,919
4,789
-18,150
-33,692
-33,692-18,1504,7894,9192,2121,05910900
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
0
0
109
1,059
2,212
4,919
4,789
-562
0
0-5624,7894,9192,2121,05910900



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue496,659
Cost of Revenue-188,157
Gross Profit308,502308,502
 
Operating Income (+$)
Gross Profit308,502
Operating Expense-269,266
Operating Income17,02739,236
 
Operating Expense (+$)
Research Development128,844
Selling General Administrative78,985
Selling And Marketing Expenses54,867
Operating Expense269,266262,696
 
Net Interest Income (+$)
Interest Income1,019
Interest Expense-13,136
Other Finance Cost-636
Net Interest Income-12,753
 
Pretax Income (+$)
Operating Income17,027
Net Interest Income-12,753
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,08747,166
EBIT - interestExpense = 3,891
3,087
18,347
Interest Expense13,136
Earnings Before Interest and Taxes (EBIT)17,02716,223
Earnings Before Interest and Taxes (EBITDA)23,770
 
After tax Income (+$)
Income Before Tax3,087
Tax Provision--2,124
Net Income From Continuing Ops5,2115,211
Net Income5,211
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses457,423
Total Other Income/Expenses Net-30,13912,753
 

Technical Analysis of Telix Pharmaceuticals Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Telix Pharmaceuticals Ltd. The general trend of Telix Pharmaceuticals Ltd is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Telix Pharmaceuticals Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Telix Pharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 13.54 > 11.82 > 11.16.

Tweet this
Telix Pharmaceuticals Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Telix Pharmaceuticals Ltd. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Telix Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Telix Pharmaceuticals Ltd. The current macd is 0.47012656.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Telix Pharmaceuticals Ltd price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Telix Pharmaceuticals Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Telix Pharmaceuticals Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Telix Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartTelix Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Telix Pharmaceuticals Ltd. The current adx is 21.31.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Telix Pharmaceuticals Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Telix Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Telix Pharmaceuticals Ltd. The current sar is 12.17.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Telix Pharmaceuticals Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Telix Pharmaceuticals Ltd. The current rsi is 70.11. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Telix Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartTelix Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Telix Pharmaceuticals Ltd. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Telix Pharmaceuticals Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Telix Pharmaceuticals Ltd Daily Stochastic Oscillator ChartTelix Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Telix Pharmaceuticals Ltd. The current cci is 211.91.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Telix Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartTelix Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Telix Pharmaceuticals Ltd. The current cmo is 51.10.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Telix Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartTelix Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Telix Pharmaceuticals Ltd. The current willr is -6.2745098.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Telix Pharmaceuticals Ltd Daily Williams %R ChartTelix Pharmaceuticals Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Telix Pharmaceuticals Ltd. The current atr is 0.59632876.

Telix Pharmaceuticals Ltd Daily Average True Range (ATR) ChartTelix Pharmaceuticals Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Telix Pharmaceuticals Ltd. The current obv is 51,471,514.

Telix Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartTelix Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Telix Pharmaceuticals Ltd. The current mfi is 64.13.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Telix Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartTelix Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Telix Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-17ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-27MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Telix Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Telix Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.107
Ma 20Greater thanMa 5012.862
Ma 50Greater thanMa 10012.143
Ma 100Greater thanMa 20011.274
OpenGreater thanClose14.280
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Telix Pharmaceuticals Ltd with someone you think should read this too:
  • Are you bullish or bearish on Telix Pharmaceuticals Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Telix Pharmaceuticals Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Telix Pharmaceuticals Ltd

I send you an email if I find something interesting about Telix Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Telix Pharmaceuticals Ltd.

Receive notifications about Telix Pharmaceuticals Ltd in your mailbox!